In non-APL AML patients, the original ISTH score failed to predict bleeding, whereas a modified score incorporating PT, platelet count, fibrinogen, LDH, and genetic positivity significantly improved predictive performance, in terms of AUC and statistical significance (AUC = 0.632, p = 0.079 vs. AUC = 0.710, p = 0.005). This evidence concerns the gene F2 and acute myeloid leukemia.